skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Mechanisms of failure of chimeric antigen receptor T-cell therapy

Li, Xiaoqing ; Chen, Weihong

Current opinion in hematology, 2019-11, Vol.26 (6), p.427-433

United States: Copyright Wolters Kluwer Health, Inc. All rights reserved

Texto completo disponível

Citações Citado por
  • Título:
    Mechanisms of failure of chimeric antigen receptor T-cell therapy
  • Autor: Li, Xiaoqing ; Chen, Weihong
  • Assuntos: HEMATOPOIETIC STEM CELL TRANSPLANTATION: Edited by David Rizzieri
  • É parte de: Current opinion in hematology, 2019-11, Vol.26 (6), p.427-433
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
  • Descrição: PURPOSE OF REVIEWAlthough chimeric antigen receptor T (CART)-cell therapy is best recognized for its antitumor effect in relapsed/refractory B-cell hematological cancers, it is still associated with a high relapse rate. RECENT FINDINGSWe firstly analyzed internal immunological and genetic reasons of CD19+ relapse after treatment for R/R B-cell hematological cancers with CART19 cells. The reasonsmurine-derived scFv may limit expansion of CART cells. Repeated antigen exposure leads to T-cell exhaustion. Activation of T cells can cause T-cell senescence and high expression of inhibitive receptors, PD-1, CTLA4, TIGIT, LAG-3, CD244, CD160, TIM3, which might be solved by some external pharmacological intervention methods [for instance, the use of FC (Fludarabine, Cyclophosphamide) lymphodepletion regimen, lenalidomide, PD-1 inhibitor, ibrutinib and humanized CD19-CART cells. Secondly, mechanism of CD19 relapse can be attributed to the preexisting of CD19 subclone, the loss or alternative RNA splicing on exon 2 of chromosome 16 on which CD19 gene is located, B-cell transcript factors – paired-box 5 (PAX5) and early B-cell factor 1 (EBF1) are down-regulated to cause lineage-switch from lymphoid to myeloid. SUMMARYAlthough different preparation techniques generates various entities of CART 19 cells, these problems could be conquered by novel agents and novel CAR system. VIDEO ABSTRACTAlthough Chimeric Antigen Receptor T (CART) cell therapy is best recognized for its antitumor effect in Relapsed/Refractory B-cell hematological cancers, it still shows a high relapse rate. We review mechanisms of failure of CART therapy. http://links.lww.com/COH/A18.
  • Editor: United States: Copyright Wolters Kluwer Health, Inc. All rights reserved
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.